Yes, hormone pellets can cause bleeding, and it’s one of the most common side effects reported by women using pellet-based hormone therapy. The bleeding happens because the estrogen released by the pellets stimulates the uterine lining to thicken. Without enough progesterone to counterbalance that effect, the lining becomes unstable and sheds irregularly. This is especially surprising for postmenopausal women who haven’t had a period in years.
Why Estrogen Pellets Cause Bleeding
Hormone pellets, typically inserted under the skin of the hip or buttock, release a steady stream of estrogen (and sometimes testosterone) over several months. That estrogen acts directly on the uterine lining, causing it to grow thicker. In a normal menstrual cycle, progesterone rises after ovulation and stabilizes the lining, then drops to trigger a controlled period. When estrogen arrives without adequate progesterone to oppose it, the lining grows in a disorganized way and can break down unpredictably, producing spotting or heavier bleeding at random times.
This concept, called “unopposed estrogen,” is the central reason pellet therapy causes uterine bleeding. It applies to any form of estrogen replacement, but pellets pose a particular challenge: once inserted, the dose can’t be adjusted or removed easily. If the estrogen level is higher than expected, or if the accompanying progesterone dose is too low, bleeding can persist for weeks.
The Role of Progesterone
Progesterone does two critical jobs in the uterus: it regulates how thick the lining gets, and it controls when and how the lining sheds. Low progesterone effectively means too much estrogen by comparison. The Cleveland Clinic lists heavy menstrual bleeding as a direct consequence of that imbalance. Even light spotting in postmenopausal women can reflect the same mechanism at a smaller scale.
For women using estrogen pellets who still have a uterus, a progestogen (synthetic or natural progesterone) is prescribed alongside the pellet to protect the lining. Guidelines from the British Menopause Society recommend a minimum of 10 to 12 days of progesterone per month in women on sequential hormone therapy. If the progesterone dose is too low, too short, or taken inconsistently, breakthrough bleeding is likely.
What the Bleeding Looks Like
Bleeding from hormone pellets varies widely. According to ACOG, postmenopausal bleeding can range from light spotting that looks pinkish-gray or brown to a flow as heavy as a regular period. Most of the time, there’s no pain with it. Some women notice it only when wiping, while others need pads or liners for several days. Bleeding after sex is also possible because estrogen changes can make vaginal tissue more sensitive, though this still warrants evaluation.
The timing matters too. Bleeding that starts within the first few months of pellet insertion is common as your body adjusts to the new hormone levels. The British Menopause Society considers unscheduled bleeding within the first six months of starting hormone therapy a normal adjustment window, provided there are no additional risk factors.
When Bleeding Is Expected to Stop
For most women, irregular bleeding improves within three to six months of starting or changing hormone therapy. If you’ve had a dose adjustment or switched preparations, the clock resets: another three months is generally allowed for the bleeding to settle. The Mayo Clinic notes that some forms of hormone therapy, particularly those using cyclic progesterone (estrogen daily plus progesterone for 10 to 14 days each month), will produce a predictable monthly bleed by design. This is normal and not a sign of a problem.
If bleeding continues beyond six months despite adjustments, guidelines recommend further investigation, typically starting with an ultrasound. Persistent or heavy bleeding that doesn’t respond to changes in your progesterone dose or schedule is the point where your provider will want to look more closely at the uterine lining.
When Bleeding Needs Investigation
Any postmenopausal bleeding deserves a conversation with your provider, even when you’re on hormone therapy. The reason is straightforward: unopposed estrogen doesn’t just cause temporary bleeding. Over time, it can cause the uterine lining to develop abnormal cell changes called endometrial hyperplasia, which is a precursor to endometrial cancer.
An ultrasound measuring the thickness of the uterine lining is usually the first step. For women on hormone therapy who are experiencing bleeding, an endometrial thickness greater than 4 to 5 millimeters typically triggers further evaluation, often a biopsy. For women on hormone therapy with no bleeding, thresholds are higher, around 8 millimeters, since the hormones themselves cause some expected thickening.
Certain risk factors raise the urgency. A history of obesity, diabetes, a family history of uterine or colon cancer, or prolonged use of unopposed estrogen all increase the likelihood that bleeding reflects something more than a hormonal adjustment issue. The British Menopause Society recommends an urgent referral for women with even one major risk factor for endometrial cancer, regardless of how long they’ve been on hormone therapy.
How Providers Manage Pellet-Related Bleeding
Because pellets can’t be dialed down once they’re in place, the usual first-line fix is adjusting the progesterone component. This might mean increasing the dose, extending how many days per month you take it, or switching to a different form entirely. A progesterone-releasing intrauterine device is one of the most effective options for reducing unscheduled bleeding compared to oral or topical progesterone.
If you’re taking separate estrogen and progesterone preparations, your provider may also look at whether a combined formulation (a single patch or pill containing both hormones) would reduce missed doses or timing errors. Adherence issues are a surprisingly common cause of breakthrough bleeding, simply forgetting a few days of progesterone can destabilize the lining enough to trigger spotting.
When bleeding settles after adjustments, some women restart or continue pellet therapy with the new progesterone regimen. If bleeding returns or persists beyond another six months, the next step is usually an ultrasound within six weeks. In cases where the ultrasound and biopsy are normal but bleeding keeps recurring, switching away from pellets to a different estrogen delivery method, or stopping hormone therapy altogether, becomes part of the conversation.
Pellets vs. Other Hormone Delivery Methods
Pellets aren’t uniquely more likely to cause bleeding than patches, pills, or creams, but they do present a unique management challenge. With a pill or patch, your provider can quickly lower the dose or pause treatment if bleeding becomes a problem. With pellets, the hormones continue releasing for three to six months after insertion. This means any dose-related bleeding has to be managed around the pellet rather than by adjusting it directly.
Oral hormone preparations actually tend to produce higher rates of no-bleeding outcomes compared to transdermal options like patches or pellets. For women who experience recurrent unscheduled bleeding with pellets and have no risk factors for blood clots, switching to an oral preparation is a reasonable option to discuss with a provider.